Sun Xueqing, Li Zhicheng, Chen Yingjie
Department of Clinical Laboratory, The People's Hospital of Dongying, Dongying, Shandong, China.
Department of Clinical Laboratory, The Second Hospital, Shandong University, Jinan, Shandong, China
Ann Clin Lab Sci. 2016 Winter;46(1):44-8.
MicroRNA-429 (miR-429) is reported to be frequently dysregulated in cancer. Studies have demonstrated that miR-429 functions as either an oncogene or a tumor suppressor depending on the tumor type. To date, its role in human glioma has not yet been reported. The aim of this study was to investigate the expression levels, clinicopathological significance, and prognostic significance of miR-429 in glioma tissues. Quantitative real-time PCR assay was performed to detect miR-429 expression in human glioma and non-neoplastic brain tissues. The association of miR-429 expression with clinicopathological features and prognoses of glioma patients were analyzed by SPSS 17.0 statistical software. The expression levels of miR-429 were found to be distinctly increased in glioma tissues compared to non-neoplastic brain tissues (P<0.01) with ascending pathological grade. The 5-year survival rate of patients with high miR-429 expression was significantly lower than those with low miR-429 expression (P<0.001). Moreover, multivariate Cox regression analyses showed that miR-429 high expression is an independent prognostic factor for glioma patients. Taken together, miR-429, was significantly up-regulated in glioma tissues. Therefore, miR-429 could be considered as an independent prognostic factor and potential therapeutic target for glioma.
据报道，微小RNA-429（miR-429）在癌症中经常发生失调。研究表明，根据肿瘤类型，miR-429既可以作为癌基因发挥作用，也可以作为肿瘤抑制因子发挥作用。迄今为止，其在人类胶质瘤中的作用尚未见报道。本研究的目的是探讨miR-429在胶质瘤组织中的表达水平、临床病理意义及预后意义。采用定量实时PCR检测人胶质瘤组织和非肿瘤脑组织中miR-429的表达。应用SPSS 17.0统计软件分析miR-429表达与胶质瘤患者临床病理特征及预后的关系。结果发现，与非肿瘤脑组织相比，miR-429在胶质瘤组织中的表达水平明显升高（P<0.01），且随着病理分级的升高而升高。miR-429高表达患者的5年生存率明显低于miR-429低表达患者（P<0.001）。此外，多因素Cox回归分析显示，miR-429高表达是胶质瘤患者的独立预后因素。综上所述，miR-429在胶质瘤组织中显著上调。因此，miR-429可被视为胶质瘤的独立预后因素和潜在治疗靶点。
